VIR,Vir Biotechnology, Inc. | Healthcare

Healthcare

VIR

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Vir Biotechnology, Inc.VIR

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.

It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.

It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus.

The company was incorporated in 2016 and is headquartered in San Francisco, California.

Latest News >

Budget 2022: Commodities market expectations from Finance Minister Nirmala Sitharaman

Jan 25, 2022

The union budget next week promises a whole host of reforms and reduction of commodity transaction tax is the top ask of the commodities market.When it comes to gold, the sector has been demanding a cut on import duty as well as on capital gains. To discuss commodity sectors budget wishlist, CNBC-TV18 spoke to Narinder Wadhwa, President of CPAI; Kunal Shah, Head, Commodities at Nirmal Bang Commodities and Kishore Narne, Head of Commodities at Motilal Oswal Commodity Broker.

View: More depreciation on cards for rupee in 2022

Jan 25, 2022

After topping near 76.30 in mid-December, the USD-INR pair as once again approached the trend-line support at around 73.50-70, according to Amit Pabari of CR Forex Advisors.

Ahead of IPO, Fabindia to reward artisans, farmers with shares

Jan 25, 2022

Fabindia is laying the ground work for Rs 4,000 crore IPO. Ahead of the public listing, the company plans to transfer some shares to artisans and farmers who are engaged with the company.

IBLA Jury | Zarin Daruwala, Salil Parekh, Suresh Narayanan and other industry captains spell their 2022 outlook

Jan 25, 2022

A PwC survey shows 99 percent of India's CEOs foresee better economic growth this year. 94 percent of global CEOs are optimistic about global economic growth improving this year compared to 77 percent last year. So what is fuelling this optimism amid the uncertainty? How will 2022 shape up for India and the world? To discuss the year gone by and their outlook for 2020 is CNBC-TV18 spoke to its esteemed IBLA jury.